Advancements in the Treatment of Desmoid Tumors : Episode 10

Opinion

Video

February 5, 2024

Targeting NOTCH Pathway Signaling with Nirogacestat

Author(s):

Jonathan C. Trent, MD, PhD,Mark Agulnik, MD

Mark Agulnik, MD, examines the mechanism of action of nirogacestat, emphasizing the impact of ϒ-secretase inhibition on NOTCH pathway signaling.

EP: 1.An Overview of the Landscape Surrounding Desmoid Tumors

EP: 2.Expert Perspectives on the Pathogenesis and Diagnosis of Desmoid Tumors

EP: 3.Signs and Symptoms of Desmoid Tumors and Their Impact on Quality of Life

EP: 4.Active Surveillance in Frontline Management of Desmoid Tumors

EP: 5.The Evolving Role of Surgery in the Management of Desmoid Tumors

EP: 6.Treatment Strategies Using Radiotherapy or Other Locoregional Approaches in Desmoid Tumors

EP: 7.Approaches to Systemic Therapy in Desmoid Tumors: The Role of Chemotherapy

EP: 8.The Role of Supportive Care Measures in Patients with Desmoid Tumors

EP: 9.Desmoid Tumors in Women: Special Considerations for Pregnancy and Contraception

EP: 10.Targeting NOTCH Pathway Signaling with Nirogacestat

EP: 11.DeFi: Nirogacestat in Patients with Progressing Desmoid Tumors

EP: 12.Impact of Nirogacestat on Pain, Quality of Life, and Fertility in Patients with Desmoid Tumors

EP: 13.Nirogacestat's Impact on the Future Treatment of Desmoid Tumors

EP: 14.Future Perspectives on the Treatment of Desmoid Tumors

Related Videos

5 KOLs are featured in this series.

5 KOLs are featured in this series.

Related Content

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment

September 15th 2021

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment

Related Content

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment

September 15th 2021

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment

Latest Conference Coverage

Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC

Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC

Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab

Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma

View More Latest Conference Coverage

Editorial Board

MJH Life Sciences brands

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.